BlackRock’s Cocrystal Pharma COCP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $77.4K | Hold |
73,746
| – | – | ﹤0.01% | 5068 |
|
|
2026
Q1 | $74.5K | Hold |
73,746
| – | – | ﹤0.01% | 5030 |
|
|
2025
Q4 | $72.2K | Hold |
73,746
| – | – | ﹤0.01% | 4974 |
|
|
2025
Q3 | $92.2K | Hold |
73,746
| – | – | ﹤0.01% | 4850 |
|
|
2025
Q2 | $110K | Hold |
73,746
| – | – | ﹤0.01% | 4824 |
|
|
2025
Q1 | $105K | Hold |
73,746
| – | – | ﹤0.01% | 4759 |
|
|
2024
Q4 | $149K | Hold |
73,746
| – | – | ﹤0.01% | 4680 |
|
|
2024
Q3 | $130K | Hold |
73,746
| – | – | ﹤0.01% | 4621 |
|
|
2024
Q2 | $172K | Hold |
73,746
| – | – | ﹤0.01% | 4580 |
|
|
2024
Q1 | $103K | Sell |
73,746
-317
| -0.4% | -$494 | ﹤0.01% | 4718 |
|
|
2023
Q4 | $128K | Hold |
74,063
| – | – | ﹤0.01% | 4748 |
|
|
2023
Q3 | $138K | Hold |
74,063
| – | – | ﹤0.01% | 4770 |
|
|
2023
Q2 | $177K | Hold |
74,063
| – | – | ﹤0.01% | 4762 |
|
|
2023
Q1 | $147K | Hold |
74,063
| – | – | ﹤0.01% | 4869 |
|
|
2022
Q4 | $144K | Buy |
74,063
+1
| +0% | +$3 | ﹤0.01% | 4938 |
|
|
2022
Q3 | $259K | Hold |
74,062
| – | – | ﹤0.01% | 4909 |
|
|
2022
Q2 | $364K | Sell |
74,062
-18,522
| -20% | -$98.7K | ﹤0.01% | 4868 |
|
|
2022
Q1 | $611K | Sell |
92,584
-1,049
| -1% | -$6.97K | ﹤0.01% | 4824 |
|
|
2021
Q4 | $730K | Buy |
93,633
+819
| +0.9% | +$8.38K | ﹤0.01% | 4760 |
|
|
2021
Q3 | $1.17M | Sell |
92,814
-2,005
| -2% | -$26.5K | ﹤0.01% | 4513 |
|
|
2021
Q2 | $1.42M | Buy |
94,819
+2,571
| +3% | +$39.1K | ﹤0.01% | 4402 |
|
|
2021
Q1 | $1.54M | Hold |
92,248
| – | – | ﹤0.01% | 4375 |
|
|
2020
Q4 | $1.5M | Buy |
+92,248
| New | +$1.28M | ﹤0.01% | 4116 |
|
|
2020
Q2 | – | Sell |
-3,040
| Closed | -$26K | – | 5020 |
|
|
2020
Q1 | $26K | Buy |
3,040
+285
| +10% | +$2.68K | ﹤0.01% | 4575 |
|
|
2019
Q4 | $16K | Sell |
2,755
-29
| -1% | -$290 | ﹤0.01% | 4689 |
|
|
2019
Q3 | $68K | Sell |
2,784
-160
| -5% | -$4.15K | ﹤0.01% | 4495 |
|
|
2019
Q2 | $83K | Buy |
2,944
+391
| +15% | +$11.6K | ﹤0.01% | 4498 |
|
|
2019
Q1 | $84K | Sell |
2,553
-175
| -6% | -$6.4K | ﹤0.01% | 4401 |
|
|
2018
Q4 | $118K | Sell |
2,728
-50
| -2% | -$1.65K | ﹤0.01% | 4326 |
|
|
2018
Q3 | $83K | Buy |
2,778
+112
| +4% | +$5.01K | ﹤0.01% | 4482 |
|
|
2018
Q2 | $117K | Buy |
+2,666
| New | +$99K | ﹤0.01% | 4440 |
|
Other funds holding COCP
XT
BlackRock's COCP Position: Q2 2026 in Review
BlackRock held its Cocrystal Pharma (COCP) position steady in Q2 2026 at 73,746 shares worth $77.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5068.
BlackRock first reported a position in COCP in Q2 2018 and has held it in 31 quarters since. The position peaked at $1.54M in Q1 2021. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.
- BlackRock held 73,746 shares of Cocrystal Pharma worth $77.4K as of Q2 2026.
- BlackRock left its Cocrystal Pharma share count unchanged in Q2 2026.
- Cocrystal Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5068 holding.
- BlackRock first reported a position in Cocrystal Pharma in Q2 2018 and has held it in 31 quarters since.
- BlackRock's Cocrystal Pharma position peaked at $1.54M in Q1 2021.
- 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.